0001839882-24-001450.txt : 20240119 0001839882-24-001450.hdr.sgml : 20240119 20240119080030 ACCESSION NUMBER: 0001839882-24-001450 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20240119 ITEM INFORMATION: Other Events FILED AS OF DATE: 20240119 DATE AS OF CHANGE: 20240119 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Rain Oncology Inc. CENTRAL INDEX KEY: 0001724979 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 821130967 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40356 FILM NUMBER: 24543773 BUSINESS ADDRESS: STREET 1: 8000 JARVIS AVENUE STREET 2: SUITE 204 CITY: NEWARK STATE: CA ZIP: 94560 BUSINESS PHONE: (510) 953-5559 MAIL ADDRESS: STREET 1: 8000 JARVIS AVENUE STREET 2: SUITE 204 CITY: NEWARK STATE: CA ZIP: 94560 FORMER COMPANY: FORMER CONFORMED NAME: Rain Therapeutics Inc. DATE OF NAME CHANGE: 20171211 8-K 1 rain_8k-011924.htm CURRENT REPORT
false 0001724979 0001724979 2024-01-19 2024-01-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 19, 2024

 

RAIN ONCOLOGY INC.

(Exact name of registrant as specified in its charter)

 

Delaware 001-40356 82-1130967

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

 

8000 Jarvis Avenue, Suite 204
Newark, California 94560
(Address of Principal Executive Offices) (Zip Code)
   

 

Registrant’s telephone number, including area code: (510) 953-5559

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered

Common Stock, $0.001 par value per share

 RAIN The Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

 

 

  

 

Item 8.01. Other Events.

 

Agreement and Plan of Merger

As previously reported, on December 13, 2023, Rain Oncology Inc. (the “Company” or “Rain”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Pathos AI, Inc., a Delaware corporation (“Parent”), and WK Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”). The Merger Agreement provides for, among other things, (i) the acquisition of the Company by Parent through a cash tender offer (the “Offer”) by Merger Sub for all of the Company’s outstanding shares of common stock (the “Common Stock”), for: (A) $1.16 per share of Common Stock, and (B) one contingent value right representing the right to receive potential cash payments of up to approximately $0.17 per share and (ii) following the completion of the Offer, the merger of Merger Sub with and into the Company (the “Merger”) with the Company surviving the Merger as a wholly owned subsidiary of Parent. In connection with the Merger Agreement and the transactions contemplated thereby, the Company filed a Solicitation/Recommendation Statement on Schedule 14D-9 with the Securities and Exchange Commission on December 27, 2023, as amended on January 16, 2024 (together with any subsequent amendments and supplements thereto, the “Schedule 14D-9”).

In connection with the proposed Merger, 15 demand letters have been sent to the Company by purported Company stockholders raising alleged disclosure deficiencies in the Schedule 14D-9 (collectively, the “Demand Letters”). The Company denies that it has violated any laws or breached any duties to the Company’s stockholders, denies all allegations in the Demand Letters, and believes that no supplemental disclosure to the Schedule 14D-9 was or is required under any applicable law, rule or regulation. However, solely to eliminate the burden and expense of potential litigation, to moot plaintiffs’ disclosure claims, to avoid potential delay or disruption to the Merger and to provide additional information to the Company’s stockholders, the Company has determined to voluntarily supplement the Schedule 14D-9 with the below disclosure. The Company believes that the disclosures set forth in the Schedule 14D-9 comply fully with applicable law and nothing in the below supplemental disclosure shall be deemed an admission of the legal necessity or materiality under applicable law of any of the disclosures set forth herein.

To the extent that information in the below supplemental disclosure differs from, or updates information contained in, the Schedule 14D-9, the information in the below supplemental disclosure shall supersede or supplement the information in the Schedule 14D-9. Except as otherwise described in the below supplemental disclosure or the documents referred to, contained in or incorporated by reference herein, the Schedule 14D-9, the annexes to the Schedule 14D-9 and the documents referred to, contained in or incorporated by reference in the Schedule 14D-9 are not otherwise modified, supplemented or amended.

Supplemental Disclosure

The following information supplements the Schedule 14D-9, and should be read in conjunction with the Schedule 14D-9, which should be read in its entirety, including the annexes thereto. All page references in the information below are references to pages in the Schedule 14D-9, and the terms used below have the meanings set forth in the Schedule 14D-9.

1.       The following disclosure amends and replaces the disclosures that previously appeared in the first full paragraph on page 8 of the Schedule 14D-9. The modified text is underlined (where added) and struck-through (where deleted) below:

“In the event that (i) the amounts deducted from the $5,000,000 reserved for the Cash CVR Payment exceed $5,000,000 in the aggregate, holders of the CVRs will not receive any Cash CVR Payments and (ii) (A) a Disposition of CVR Products does not occur within the Disposition Period, and (B) the Development Milestone is not achieved within the Development Milestone Period, holders of the CVRs will not receive any Development CVR Payments. In such circumstances, no amounts may be payable at all in respect of the CVR Agreement. The date on which the Development Milestone Period expires is the “Development CVR Payment Expiration Date;” provided, that to the extent a Disposition of certain CVR Products takes place during the Disposition Period or the Development Milestone is achieved during the Development Milestone Period, the Development CVR Payment Expiration Date (in the case of a Disposition, solely as it relates to the CVR Products in such Disposition) shall be the earlier to occur of ten (10) years following the Effective Time and the mailing by the Rights Agent to the address of each CVR Holder of all potential contingent payments (if any) required to be paid under the terms of the CVR Agreement. As discussed in “—Opinion of Leerink Partners LLC,” given the speculative and contingent nature of the Development CVR Payment payable pursuant to the CVR Agreement, Rain management directed Leerink Partners to ascribe no value to the Development CVR Payment for purposes of Leerink Partners’ fairness opinion.”

  

 

2.       The following disclosure amends and replaces the disclosures that previously appeared in the second full paragraph on page 9 of the Schedule 14D-9. The modified text is underlined (where added) and struck-through (where deleted) below:

“With the consent of the Advisory Group (as defined in the CVR Agreement), which consists of Avanish Vellanki, Rain’s Chief Executive Officer and a Rain stockholder certain CVR Holders who havehas entered into an engagement agreement with the Representative, Parent, Merger Sub, and the Representative may amend the CVR Agreement, even if such change is materially adverse to the interests of the CVR Holders.”

3.       The following disclosure amends and replaces the disclosures that previously appeared in the second full paragraph on page 17 of the Schedule 14D-9. The modified text is underlined (where added) and struck-through (where deleted) below:

“On June 11, 2023, at a meeting of the Rain Board, also attended by Rain management and outside counsel for the Company from Gibson, Dunn & Crutcher LLP (“Gibson Dunn”), the Rain Board approved the formation of a transaction committee (the “Transaction Committee”) that comprised of Mr. Vellanki and independent directors Franklin Berger, Peter Radovich and Stefani Wolf. The Transaction Committee was formed in order to allow for a more expedient process and engagement with a subset of the Rain Board and was not formed due to any actual or perceived conflict of interest. The Transaction Committee was not formed as a formal subcommittee of the Rain Board, was not formally delegated any powers of the Rain Board and its members were not paid any compensation specifically in consideration of their service on the Transaction Committee. The Rain Board discussed and agreed that the Transaction Committee would meet regularly to review and evaluate management updates and progress against the strategic paths discussed above and would provide updates to the full Rain Board, as appropriate. Additionally, the Rain Board discussed Tang Capital’s equity ownership, its potential impact on the Company, and the likely potential objectives of Tang Capital. For each meeting of the Rain Board or Transaction Committee detailed below, Gibson Dunn was in attendance and the potential transactions were discussed in the context of the Rain Board’s fiduciary duties to stockholders.”

4.       The following disclosure amends and replaces the disclosures that previously appeared in the second sentence of the fourth full paragraph on page 24 of the Schedule 14D-9. The modified text is underlined (where added) and struck-through (where deleted) below:

“On November 7, 2023, Rain executed a confidentiality agreement, including a standstill provision and a provision that terminates the standstill upon Rain’s public announcement of its entry into a change of control transaction, with Concentra and invited representatives of Concentra to the Company’s confidential data room.”

Cautionary Note Regarding Forward-Looking Statements

This communication contains forward-looking statements related to Rain Oncology Inc. (the “Company”) and the acquisition of the Company by Pathos AI, Inc. (“Parent”), including express or implied forward-looking statements about the Company’s products and the future operations and performance of the Company and Parent. These forward-looking statements are within the meaning of U.S. federal securities laws, including, without limitation, statements regarding the anticipated timing of and closing of the proposed Offer, Merger and related transactions contemplated by the Merger Agreement (collectively referred to as the “transactions”). The words “estimates,” “expects,” “continues,” “intends,” “plans,” “anticipates,” “targets,” “may,” “will,” “would,” “could,” “should,” “potential,” “goal,” and “effort” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements are based on current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. The Company cautions that a number of important factors, including those described in this communication, could cause actual results to differ materially from those contemplated in any forward-looking statements. Any forward-looking statements in this communication are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this communication, including, without limitation, the impact of actions of other parties with respect to the transactions; the possibility that competing offers will be made; the outcome of any legal proceedings that have been or could be instituted against the Company or its directors; the potential impact of the Demand Letters or potential litigation on the timing of the transactions; the risk that the transactions may not be completed in a timely manner, or at all, which may adversely affect the Company’s business and the price of its common stock; the failure to satisfy all of the closing conditions of the transactions contemplated by the Merger Agreement; the occurrence of the events or achievement of the milestones giving rise to payments under the CVR Agreement; the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement; the effect of the announcement or pendency of the transactions on the Company’s business, and operating results; risks that the transactions may disrupt the Company’s current plans and business operations; risks related to the diverting of management’s attention from the Company’s ongoing business operations; general economic and market conditions and the other risks identified in the Company’s filings with the U.S. Securities and Exchange Commission (“SEC”), including its most recent Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 9, 2023 and subsequent filings with the SEC. Should any risks and uncertainties develop into actual events, these developments could have a material adverse effect on the transactions and/or the Company and the Company’s ability to successfully complete the transactions and, with respect to any CVR payment amounts, the consideration ultimately paid to Company stockholders (including whether any payments will be payable at all). In addition, unlisted factors may present significant additional obstacles to the realization of forward-looking statements. The Company cautions investors not to place undue reliance on any forward-looking statements. Any forward-looking statements contained in this communication represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

  

 

Additional Information and Where to Find It

This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell shares, nor is it a substitute for the tender offer materials that Parent and its subsidiary have filed with the SEC. At the time the tender offer was commenced, Parent and its subsidiary filed tender offer materials on Schedule TO, and, thereafter, the Company filed a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer.

THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT CONTAIN IMPORTANT INFORMATION. HOLDERS OF SHARES OF THE COMPANY’S COMMON STOCK ARE URGED TO READ THESE DOCUMENTS CAREFULLY (AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME) BECAUSE THEY CONTAIN IMPORTANT INFORMATION THAT HOLDERS OF SHARES OF THE COMPANY’S COMMON STOCK SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES.

The Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, have been made available to all holders of shares of the Company’s common stock at no expense to them. The tender offer materials and the Solicitation/Recommendation Statement are available for free at the SEC’s website at www.sec.gov or by accessing the Investor Relations section of the Company’s website at https://investors.rainoncology.com/.

 

  

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  RAIN ONCOLOGY INC.
     
Date: January 19, 2024 By: /s/ Avanish Vellanki
    Avanish Vellanki
    Chairman and Chief Executive Officer

 

 

  

 EX-101.SCH 2 rain-20240119.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 rain-20240119_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Entity Information, Former Legal or Registered Name EX-101.PRE 4 rain-20240119_pre.xml XBRL PRESENTATION FILE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.23.4
Cover
Jan. 19, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 19, 2024
Entity File Number 001-40356
Entity Registrant Name RAIN ONCOLOGY INC.
Entity Central Index Key 0001724979
Entity Tax Identification Number 82-1130967
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 8000 Jarvis Avenue
Entity Address, Address Line Two Suite 204
Entity Address, City or Town Newark
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94560
City Area Code (510)
Local Phone Number 953-5559
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 par value per share
Trading Symbol RAIN
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Entity Information, Former Legal or Registered Name Not Applicable
XML 6 rain_8k-011924_htm.xml IDEA: XBRL DOCUMENT 0001724979 2024-01-19 2024-01-19 iso4217:USD shares iso4217:USD shares false 0001724979 8-K 2024-01-19 RAIN ONCOLOGY INC. DE 001-40356 82-1130967 8000 Jarvis Avenue Suite 204 Newark CA 94560 (510) 953-5559 Not Applicable false false false false Common Stock, $0.001 par value per share RAIN NASDAQ true false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( Y ,U@'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " .0#-8;Z*)!>X K @ $0 &1O8U!R;W!S+V-O&ULS9+! M:L,P#(9?9?B>R$[*8";UI:.G#@8K;.QF;+4UBQ-C:R1]^SE9FS*V!]C1TN]/ MGT"-"=+T$9]C'S"2PW0W^K9+TH0U.Q$%"9#,";U.94YTN7GHH]>4G_$(09L/ M?42H.+\'CZ2M)@T3L @+D:G&&FDB:NKC!6_-@@^?L9UAU@"VZ+&C!*(4P-0T M,9S'MH$;8((11I^^"V@7XES]$SMW@%V28W)+:AB&MW!= M(MT9S+^2DW0.N&;7R:_UYG&_9:KBU:K@HA />U%+SF6U>I]621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M Y ,UA"Z]P8P 0 ( 2 8 >&PO=V]R:W-H965T&UL MC9AO<^(V$,;?WZ?0T$[G;B8)EOF? C,<2:[&V#0U:]XDMO$^_FE7?K16?Z?TD]EP;LES'$DSJ&VL3:[K=1-L>,S,E4JX MA%]62L?,PJE>UTVB.0NSH#BJ^Y[7KL=,R-JPGUV;Z6%?I382DL\T,6D<,_WR MD4=J-ZC1VNN%1['>6'>A/NPG;,WGW'Y+9AK.ZKE**&(NC5"2:+X:U$;T^J/? M<0'9'7\(OC-'Q\0-9:G4DSN9A(.:YXAXQ /K)!C\V_(QCR*G!!P_#J*U_)DN M\/CX5?TN&SP,9LD,'ZOHNPCM9E#KUDC(5RR-[*/:_<8/ VHYO4!%)OM+=OM[ M6WZ-!*FQ*CX$ T$LY/X_>SXDXBB@24\$^(< /^/>/RBCO&&6#?M:[8AV=X.: M.\B&FD4#G)"N*G.KX5 MW_QO>!T(<@P_Q_ SO0:&0?X>+8W54*A_RHCV"LUR!3=[KTW" CZHP?0T7&]Y M;?C+3[3M_8KP-7*^!J8^O%%!"G/1DL5+PLO@\/#NY1<$HIE#-%&5$1"$&<5= MQ-9E%'C\BD6&(QRMG*-U7C)F7 L5DEL9$IA\I7G!E?)I5#6/VCE:&Q6\E5;8 M%W(G(DZF:;PLG]NXAN?1RZ;7:+41GD[.TSF'YY&OA9O9D+,IBTL3A>L\CB;3 M=P_3\867@&B-!FK%!(*>55A::4KU&]N,<@C7Z?G0(["$-S07+P>D'NXCSS( M3W'W M?@LX=F=0Z(7:R5(X7&[*=TP_863%@D!Q1W]+EL_!F59;(8/R*N.:XQ&&5JP1 M%+?VMV@S92R8S%\B.?UBX(J]9JOM86S%(D%QA\\*.((F]C0*+O"^1;T/&$JQ M/E#9#"?"MM.2J4W/R$GF!N5?!T07[VKJ '(0G39,NBE),$AFLV3*/8 MQ1+@XYZ]T"QTTV_^$B]5Z>2K$' -'$926+Z/V_-KQLCM<[!A+U_EM??QERO798^@8+=. =)F"RO+2YH-=I;^(73^Q7? ^[KGX=D MJN E5>2;X<1N..3.NA6QEO%DN7/ZZZ>S;"=I=67= MA['-HN6/O.-%Q[I#)6 M,>=56R=M8SDK6W!2,EG>W&2)8D+38JT[=:=<2PZFTVY#;VA2K"NCSY:4!H-? MRA0GCTQNZ)9)L;=B6,N4D*=@7H+A8*2QQ'DJ?$,78&F? KP(&K XU7=>&18/QA<0&>7=J?$,:\M.B^4M M/3L,/S[)WMB2VSG-@DZF8BUY!72LJ(_PZTR3 .B<45XH!:N-9@.'R6,4?-@# ME_(!6OBMNHK=5R3TXE,);2"PU4GTA$8QA D*Q+^,%F)?A+W]K;"D$8_&?>S\ M;O2@?^^,X_>65Z(?]+Z:\V/1%WATUC3R]$&*6BL>]O[+"8LUF_S(T5CQY+/! MI!R\@5M*'KEUXG!I^6%9L^.]FZ:IKW#.RW^0\Y^M<\TUMTQ>DO:C_S=7^2V, MD_'T7!S1JP,Z6PEY7>>9 ]IV03NA1.XJRY/K%.?7A'=O["_PJOE]? M\HIUTNUF<$//\A=>BD[E\ZI[J,NXZBQ_AOMHD M\%G'!QR>(W?#$T%^@2O M&+(=/EB>N$_NG_A.\SQ-LPRKZ'8;9;#%ZI9E\!>/AG$##RP/9'I;K?%NXQ/R M^AQ@/7UM0K"=XI.([12O-2#QNH%'GL>[C>4!#ZP+V.Q _G@>F*FX3YI"5S%N MV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@"IQ%', ; 4/2='@/ M/GL?)=-[*CG_5U/\!%!+ P04 " .0#-8EXJ[', 3 @ "P %]R M96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_: MI7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$ MVV-#L%HL/D N&6:WO606IW.D5XA-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH M^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0 ( Y ,UBJQ"(6,P$ "(" M / >&PO=V]R:V)O;VLN>&ULC5'1;L(P#/R5*A^P%K0A#5%>0-N0I@V- MB??0NM0BB2O'A8VOG]NJ&M)>]I31=B;FJ19IZFL:C! MVWA'#02=5,3>BD(^IK%AL&6L <2[=)IEL]1;#&:Y&+6VG-X"$B@$*2C9$7N$ M2_R==S Y8\0#.I3OW/1W!R;Q&-#C%B/%*0:S;%4S.Y68R#/; M@L4?>M>9_+2'V#-B#Q]6C>1FEJE@A1REW^CUK7H\@RX/J!5Z0B? :ROPS-0V M&(Z=C*9(;V+T/8SG4.*<_U,C5146L*:B]1!DZ)'!=09#K+&))@G60VY6= ;N M\N@#FW+()FKJIBF>HPYX4P[V1D\E5!B@?%.9J+SV4VPYZ8Y>9WK_,'G4'EKG M5LJ]AU>RY1AQ_)[E#U!+ P04 " .0#-8)!Z;HJT #X 0 &@ 'AL M+U]R96QS+W=O[IFBG#S^0W1UW6E\./VR./ / M,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@;6E6?;!/3K3G M>1,)KM\,<'AT_@%02P,$% @ #D S6&60>9(9 0 SP, !, M !;0V]N=&5N=%]4>7!E&ULK9--3L,P$(6O$F5;)2XL6*"F&V +77 ! M8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5!TYB M'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T.EY&TWP39G M8ED\C<+,:DH9HS5*$M?%P>L?E.I$J+EST&!G(BY84(JKA%SY'7#J>SM 2D9# ML9&)7J5CE>BM0#I:P'K:XLH90]L:!3JHO>.6&F,"J;$#(&?KT70Q32:>,(S/ MN]G\P68*R,I-"A$YL01_QYTCR=U59"-(9*:O>"&R]>S[04Y;@[Z1S>/]#&DW MY(%B6.;/^'O&%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4 " . M0#-8!T%-8H$ "Q $ @ $ 9&]C4')O<',O87!P M+GAM;%!+ 0(4 Q0 ( Y ,UAOHHD%[@ "L" 1 " M :\ !D;V-0&UL4$L! M A0#% @ #D S6$+KW!C ! @!( !@ ("!#0@ 'AL M+W=O7!E&UL4$L%!@ ) D /@( %<4 $! end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 1 25 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://rainoncology.com/role/Cover Cover Cover 1 false false All Reports Book All Reports rain-20240119.xsd rain-20240119_lab.xml rain-20240119_pre.xml rain_8k-011924.htm http://xbrl.sec.gov/dei/2023 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "rain_8k-011924.htm": { "nsprefix": "RAIN", "nsuri": "http://rainoncology.com/20240119", "dts": { "schema": { "local": [ "rain-20240119.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "rain-20240119_lab.xml" ] }, "presentationLink": { "local": [ "rain-20240119_pre.xml" ] }, "inline": { "local": [ "rain_8k-011924.htm" ] } }, "keyStandard": 25, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 60, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 25 }, "report": { "R1": { "role": "http://rainoncology.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-01-19", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "rain_8k-011924.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-01-19", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "rain_8k-011924.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityInformationFormerLegalOrRegisteredName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInformationFormerLegalOrRegisteredName", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Information, Former Legal or Registered Name", "documentation": "Former Legal or Registered Name of an entity" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://rainoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 13 0001839882-24-001450-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001839882-24-001450-xbrl.zip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